Close Menu

Now that Pfizer's acquisition of Wyeth is complete, the cuts are coming -- this week, the pharma announced that it would shut down six of its 20 research facilities (with some question marks hanging over others). "Pfizer didn't say how many R&D jobs it would cut or how much it hoped to save from the shutdowns," according to this news analysis story from the Wall Street Journal.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.